Understanding the Black Box Warnings for JAK Inhibitors

Linda Stein Gold, MD, provides an overview of the four JAK inhibitors currently available for treating inflammatory diseases.

Key opinion leaders explain the box warnings and safety profiles of JAK inhibitors.

Matthew Zirwas, MD, breaks down the safety of JAK inhibitors based on clinical trial data.

Clinicians provide insight into the risk of high systemic absorption levels with JAK inhibitor treatments.

Dr Matthew Zirwas describes his experience using JAK inhibitor ruxolitinib in his clinical practice.

Linda Stein Gold, MD, and Matthew Zirwas, MD, share some advice for clinicians on how to discuss JAK inhibitors with patients.

Experts outline strategies for patient conversations around the black box warning.